Price Chart

Profile

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
URL https://www.ainos.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 07, 2025 (est.)
Last Earnings Release Nov. 06, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
URL https://www.ainos.com
Investor Relations URL N/A
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 07, 2025 (est.)
Last Earnings Release Nov. 06, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A